Distinguishing aggregate formation and aggregate clearance using cell-based assays
Eenjes, Evelien; Dragich, Joanna M.; Kampinga, Harm H.; Yamamoto, Ai

Published in: Journal of Cell Science

DOI: 10.1242/jcs.179978

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2016

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Distinguishing aggregate formation and aggregate clearance using cell-based assays

Evelien Eenjes1,2,*, Joanna M. Dragich1, Harm H. Kampinga2 and Ai Yamamoto1,3,‡

INTRODUCTION

The accumulation of ubiquitylated proteinaceous inclusions represents a complex process, reflecting the disequilibrium between aggregate formation and aggregate clearance. Although decreasing aggregate formation or augmenting aggregate clearance will ultimately lead to a diminished aggregate burden, in terms of disease pathogenesis, the different approaches can have distinct outcomes. Using a novel cell-based assay that can distinguish newly formed versus preformed inclusions, we demonstrate that two proteins previously implicated in the autophagic clearance of expanded polyglutamine inclusions, HspB7 and Alfy (also known as WDFY3), actually affect very distinct cellular processes to affect aggregate burden. Using this cell-based assay, we also establish that constitutive expression of the aggregation-prone protein can measurably slow the elimination of protein aggregates, given that not all aggregates appear to be available for degradation. This new assay can therefore not only determine at what step a modifier might influence aggregate burden, but also can be used to provide new insights into how protein aggregates are targeted for degradation.

KEY WORDS: Protein aggregation, Polyglutamine protein, Chaperone, Autophagy

ABSTRACT

The accumulation of ubiquitylated proteinaceous inclusions represents a complex process, reflecting the disequilibrium between aggregate formation and aggregate clearance. Although decreasing aggregate formation or augmenting aggregate clearance will ultimately lead to a diminished aggregate burden, in terms of disease pathogenesis, the different approaches can have distinct outcomes. Using a novel cell-based assay that can distinguish newly formed versus preformed inclusions, we demonstrate that two proteins previously implicated in the autophagic clearance of expanded polyglutamine inclusions, HspB7 and Alfy (also known as WDFY3), actually affect very distinct cellular processes to affect aggregate burden. Using this cell-based assay, we also establish that constitutive expression of the aggregation-prone protein can measurably slow the elimination of protein aggregates, given that not all aggregates appear to be available for degradation. This new assay can therefore not only determine at what step a modifier might influence aggregate burden, but also can be used to provide new insights into how protein aggregates are targeted for degradation.

KEY WORDS: Protein aggregation, Polyglutamine protein, Chaperone, Autophagy

TOOLS AND TECHNIQUES

Received 2 September 2015; Accepted 21 January 2016

aggregate clearance can be directly affected by the presence of newly formed protein. This new assay can therefore not only determine at what step a modifier might impact on aggregate burden, but can be used to provide new insights into how protein aggregates are readied for degradation.

RESULTS
HspB7 and AlfyC decrease the aggregation of transiently transected polyQ protein
HspB7 is a poorly characterized small heat-shock protein that is expressed primarily in cardiac and skeletal muscle (Vos et al., 2009). In a screen examining which small heat-shock proteins influence the detergent solubility of expanded polyQ proteins, transient overexpression of HspB7 was effective at preventing inclusion formation and diminishing toxicity in a fly eye model of polyQ toxicity, whereas HspB2, HspB3, HspB5 and HspB10 were not (Vos et al., 2010). To replicate the efficacy of HspB7, we transiently overexpressed polyQ proteins were not explored, we next co-transfected a 17-amino-acid fragment of the huntingtin protein (17aaHtt) carrying an expanded polyQ mutation of 103 residues with a monomeric CFP (mCFP) tag (17aaHtt103Q–mCFP) (Yamamoto et al., 2006) with HspB7 or control (Ctrl, empty vector) (Fig. 1A). To measure the amount of SDS-insoluble proteins and soluble polyQ proteins, we used a filter-trap assay (FTA) (Fig. 1Ai,ii) and western blotting (Fig. 1Aiii,iv), respectively. As previously shown, at 24 h post-transfection, overexpression of HspB7 dramatically reduced the amount of insoluble polyQ protein. Unlike previous reports that showed no effect on the SDS-soluble fraction (Filimonenko et al., 2010), however, we found a modest but significant increase in the presence of HspB7.

Next, we performed similar experiments with Alfy (Fig. 1B). Alfy has been shown to be an adaptor for the selective macroautophagy-dependent degradation of ubiquitylated aggregates (Simonsen et al., 2004; Filimonenko et al., 2010; Clausen et al., 2010). We have previously reported that the overexpression of full-length Alfy or a 100-kDa C-terminal fragment of Alfy (AlfyC), which contains all the functional domains that are required to assist with macroautophagy, is sufficient to increase clearance of polyQ aggregate in stably transfected cell lines, a primary neuronal model and a transgenic fly eye model (Filimonenko et al., 2010). Given that transiently overexpressed polyQ proteins were not explored, we next co-transfected AlfyC with 17aaHtt103Q–mCFP. Similar to with HspB7, co-transfection of AlfyC decreased the SDS-insoluble fraction of 17aaHtt103Q–mCFP (Fig. 1B). Consistent with previous reports (Filimonenko et al., 2010), no change in SDS-soluble protein levels was observed. These data indicate that HspB7 and AlfyC can both diminish the amount of insoluble 17aaHtt103Q–mCFP caused by transient transfection of this expanded polyQ protein, whereas the SDS-soluble protein is differentially affected.

AlfyC, but not HspB7, stimulates clearance of preformed aggregates
Although HspB7 and AlfyC affected the amount of SDS-insoluble polyQ inclusions, co-transfection of a potential modifier with the aggregation-prone protein makes it difficult to determine when the modifier acts on its target. For example, as a chaperone protein, HspB7 might interfere with aggregate formation by maintaining the solubility of the expanded polyQ protein, or it might decrease the levels of polyQ oligomers or aggregates by increasing their degradation. To investigate further how HspB7 and AlfyC impacts on insoluble polyQ protein, we used a tetracycline (tet)-regulatable cell line stably expressing 17aaHtt103Q–mCFP or a similar construct with 65 polyQ residues (17aaHtt65Q–mCFP) (Fig. S1) (Yamamoto et al., 2006). Similar to in disease conditions, these cell lines demonstrate a steady state level of preformed inclusions when maintained in the ‘tet-on’ state, in which 30 to 40% of the cells are positive for aggregates. To eliminate expression, cells are exposed to doxycycline (dox), upon which clearance of aggregates is revealed. Thus, for these experiments, the polyQ-
expressing cells were maintained continuously without dox, to maintain the presence of preformed aggregates. First, we overexpressed AlfyC in these cell lines. Similar to in conditions of transient expression, 72 h of AlfyC overexpression decreased the amount of insoluble polyQ protein under conditions of stable polyQ expression (Fig. 2Ai,ii). Levels of SDS-soluble 17aaHtt65Q were unaffected by AlfyC overexpression, consistent with Alfy being an adaptor for aggregated proteins (Fig. 2Aiii,iv).

We next determined whether HspB7 could reduce the levels of insoluble polyQ proteins under these conditions (Fig. 2B). Despite the robust response we observed in Fig. 1A, overexpression of HspB7 had no effect on either the SDS-soluble or -insoluble pool of polyQ protein in cells stably expressing 17aaHtt65Q–mCFP (Fig. 2Bi–iv) or 17aaHtt103Q–mCFP (Fig. S1). To confirm our findings, we also counted the number of CFP-positive inclusions per cell, which also showed no difference between HspB7 and control transfections (Fig. 2Bv,vi; Fig. S1C). These data indicate that unlike AlfyC, HspB7 cannot eliminate preformed polyQ inclusions, suggesting that these two proteins act in different pathways to affect the aggregate burden in cells.

**Clearance of accumulated protein in inducible cell line expressing HaloTag-fused polyQ**

Our findings represented in Figs 1 and 2 give rise to the question, when does HspB7 or Alfy exert its effect on aggregation? By merely relying on a single fluorophore tag, we are prevented from temporally distinguishing the aggregation events occurring in the cells. Thus, to permit the study of polyQ aggregation over time, we...

---

**Fig. 2. Overexpression of AlfyC but not HspB7 leads to a decrease in the amount of preformed 17aaHtt65Q aggregates in a stably expressing polyQ cell line.** (A) AlfyC was transfected into a stable cell line expressing 17aaHtt65Q–mCFP. The stable cell lines are maintained in the absence of dox, and are thus under continuous expression. Samples for FTA (i,ii) and western blotting (iii,iv) were prepared at 72 h post-transfection (n=3). AlfyC diminishes the amount of detergent-insoluble aggregated protein [F(1, 4)=55.902; *P=0.0017] (i,ii); however it has no effect on SDS-soluble 17aaHtt65Q [F(1, 4)=0.063; *P=0.8137] (iii,iv). (B) HspB7 was transfected under the same conditions as A, and samples were prepared for FTA (i,ii) after 24 (n=4), 48 (n=4) or 72 (n=3) hours post-transfection, and western blot analysis (iii,iv) after 24 (n=3), 48 (n=3) or 72 (n=2) hours post-transfection. Both show that HspB7 has no effect on the amount of SDS-insoluble [F(1, 16)=0.539; *P=0.4734] or SDS soluble [F(1, 16)=0.670; *P=0.4321] 17aaHtt65Q–mCFP protein. Western blotting also shows that HspB7 protein decreased in levels within 72 h after transfection. (v,vi) Image-based analysis also reveals that HspB7 does not influence the percentage of cells with 17aaHtt103Q–mCFP aggregates (green) [F(1, 6)=0.366; *P=0.5672]. Nuclei are stained with Hoechst 33342 (blue). 100 cells were counted per experimental replicate (n=2). Data represented as mean+s.d. from the number of independent experiments indicated above. Scale bars: 10 μm. Two-tailed ANOVAs were performed to determine statistical significance. Ctrl, empty vector.

---

1262
created an inducible stable cell line expressing an exon 1 fragment of Htt with 103 polyQ residues (exon1Htt103Q) tagged with HaloTag (exon1Htt103Q–HaloTag) (Fig. 3). HaloTag-fused proteins can be irreversibly labeled with fluorescent dyes such as tetramethylrhodamine (TMR), Oregon Green or coumarin that have been covalently linked to a haloalkane component (Los et al., 2008). Given that ligand binding is irreversible, different fluorescent ligands can be used to pulse-label and study aggregation over time (Fig. S2A). To offer further experimental flexibility, we also used a tet-regulatable design (Fig. S2B) to permit comparison with existing single fluorophore cell lines, such as the 17aaHtt103Q–mCFP used in Fig. 2.

We have previously found that in our tet-regulatable cells stably expressing 17aaHttpolyQ–mCFP shutting off gene expression using dox leads to aggregate clearance in 3 to 5 days (Fig. S1) (Yamamoto et al., 2006). To ensure that the HaloTag tag did not affect aggregation or clearance, we examined tet-regulatable aggregate clearance in the exon1Htt103Q–HaloTag cells (Fig. 3). First, to ensure that HaloTag did not affect aggregation, cells were maintained in the gene-on state (i.e. no dox) for several passages, then exposed to TMR. We found that TMR-positive aggregates were recognized by the EM48 antibody, indicating that they were specific for the exon1Htt103Q protein (Fig. 3A). Next, using the HaloTag, we examined aggregate clearance with TMR and Oregon Green to label the different populations of exon1Htt103Q (Fig. 3B). Initially, prior to dox administration, TMR was added to label all of the existing exon1Htt103Q present before shutting off gene expression. Next, dox was administered to shut off exon1Htt103Q expression. After 0 to 96 h and, prior to fixation, Oregon Green was used to label any exon1Htt103Q that might have been newly expressed after dox treatment. Oregon-Green-positive protein would therefore be indicative of any significant leakiness of the tet-regulation.

Image-based analysis at time 0 h revealed that TMR efficiently labeled aggregate-like structures (Fig. 3B,C). At steady state, 40 to 50% of cells contained TMR-positive aggregates, but none were positive for Oregon Green (Fig. 3C,D), indicating that the concentration of TMR used fully occupied the available HaloTag-binding sites, exposure to dox led to a decrease in the number of cells with aggregates over time. All TMR-positive aggregates were eliminated after 72 h of dox, although a substantial decrease occurred within 48 h (Fig. 3C,D). When examining for Oregon Green staining, there were no aggregates positive for Oregon Green, indicating that there was no detectable leakiness of exon1Htt103Q–HaloTag expression after dox treatment (Fig. 3C,D).

FTA and immunoblotting analyses against the HaloTag tag also showed that under similar conditions, there were no longer...
detectable levels of SDS-insoluble and soluble exon1Htt103Q–HaloTag protein after 48 h and 24 h, respectively (Fig. 4A). Lysosomal inhibition using 10 μM chloroquine (Chlor) significantly impeded the clearance of the insoluble polyQ but not of soluble polyQ protein (Fig. 4B), suggesting that only the aggregates were being degraded by macroautophagy, consistent with the data collected from mCFP-tagged cells lines (Yamamoto et al., 2006; Filimonenko et al., 2010). To determine whether exon1Htt103Q–HaloTag colocalizes to autophagosomes, we next examined primary cortical neurons generated from mice expressing a GFP-tagged form of the mammalian homolog of Atg8, MAP1 light chain 3B (LC3, also known as MAP1LC3B) (Mizushima et al., 2004), an autophagosome marker (Kabeya et al., 2000). Primary cortical neurons were transiently transfected with exon1Htt103Q–HaloTag and then exposed to TMR. Confocal microscopy revealed that TMR-positive structures colocalized to GFP–LC3 positive structures (Fig. 4C). In summary, these data indicate that the exon1Htt103Q–HaloTag can be used to monitor the formation and clearance of aggregated polyQ proteins.

**HaloTag tracks the formation and clearance of aggregates over time**

Although using the tet-regulatable system in different systems has revealed that mitotic and postmitotic cells have the innate capacity to eliminate protein aggregates (Filimonenko et al., 2010; Yamamoto et al., 2006, 2000), it remains uncertain whether aggregate clearance can still occur under conditions of continuous expression. This apparent subtlety is relevant because it more accurately reflects the physiological conditions under which aggregate clearance would be occurring. It is plausible that under continuous expression, seeded aggregates would continue to evolve, owing to the continuous addition of newly forming oligomers. In this model, growing aggregates might not be properly targeted and/or trafficked for degradation. Additionally, the study of aggregate clearance in dividing cells can be further

![Fig. 4. The exon1HTT103Q–HaloTag aggregates are cleared in a lysosome-dependent manner. (A) FTA (i,ii) and western blotting (iii,iv) were used to study the clearance of exon1Htt103Q–HaloTag (103Q-HT or HT) protein. Membranes were probed with an anti-HaloTag antibody. (i,ii) Detergent-insoluble exon1Htt103Q–HaloTag protein could no longer be detected after 48 h. Based on Fig. 3, this suggests that image-based analysis might be more sensitive for analysis of clearance in this cell line. (iii,iv) Western blot analysis shows that detergent-soluble protein is cleared within 24 h. (B) Exon1Htt103Q–HaloTag cells were exposed to 1 μg/ml dox without or with 10 μM of the lysosome inhibitor chloroquine (Chlor) for 48 h. Samples were analyzed by FTA (i,ii) or western blotting (iii). The presence of Chlor significantly impeded the clearance of the detergent insoluble protein \[ F(2, 6)=214.395, P=0.0015 \]. Lysosomal inhibition did not retard the clearance of soluble exon1Htt103Q protein \[ F(2, 6)=2578.875, P=0.8616 \]. The accumulation of LC3 II (the lipidated form of LC3) signifies diminished autophagosome maturation, confirming lysosome inhibition. (C) Exon1Htt103Q–HaloTag colocalizes with GFP–LC3 in primary neurons. Primary cortical neurons generated from GFP–LC3 transgenic mice were transiently transfected with exon1Htt103Q–HaloTag, and exposed to TMR 24 h later. Data represented as mean±s.d. from n=3 independent experiments. Scale bar: 10 μm. Two-tailed ANOVAs were performed to determine statistical significance.](https://doi.org/10.1242/jcs.179978)
confounded by cytoplasmic dilution and asymmetric segregation (Rujano et al., 2006). Although the HaloTag will not necessarily eliminate the impact of dilution or segregation, unlike using a single fluorophore tag, a single population of aggregates can be tracked over time, despite the addition of new protein, thus making the confounds due to cell division less invisible. Therefore, we next used the exon1Htt103Q–HaloTag cell line to determine whether aggregates are degraded during constitutive expression of the polyQ protein (Fig. 5).

To differentially label the pools of exon1Htt103Q, TMR and Oregon Green were used at different times. Similar to Fig. 3, cells were allowed to attain steady state under tet-on conditions. At time 0, cells were exposed to TMR to label all of the pre-existing protein. Next, to label the subsequently formed protein and aggregates, cells were labeled with Oregon Green 0, 24, 48, 72 or 96 h later, and then collected for analyses (Fig. 5A). First, TMR-positive versus the Oregon-Green-positive staining was examined. At time 0, similar to in Fig. 3D, there were many TMR-positive structures, but no Oregon-Green-only aggregates present (Fig. 5B). As time progressed, the number of TMR-positive aggregates decreased as the number of Oregon-Green-positive aggregates increased (Fig. 5C,D). These data indicate that aggregate clearance occurs despite continuous expression of exon1Htt103Q–HaloTag, and that clearance occurred in the background of new aggregates being formed. Furthermore, the rate at which the number of Oregon-Green-positive aggregates fell (44±17% to 28±9% compared to that at which the number TMR-positive aggregates fell (44±17% to 28±9%; mean±s.d. from n=4 independent experiments) suggests that the rate at which aggregates form is greater than the rate at which they are cleared. Finally, even after 96 h, the number of TMR-positive aggregates did not fully decline, indicating that although clearance can occur, TMR-positive structures persist much longer under constitutive expression of mutant protein than when mutant protein expression is eliminated after aggregate formation.

The analyses performed thus far examined the TMR-staining and Oregon Green staining independently of each other. As shown in Fig. 5C, the addition of Oregon Green after TMR can lead to the formation of aggregates that are positive for both ligands. This colocalization indicates the incorporation of newly formed Oregon-Green-positive protein into the pre-existing TMR-positive aggregates. This was confirmed by confocal analysis. When TMR was added 24 h after another HaloTag-ligand coumarin, coumarin-positive aggregates can be found surrounded by TMR-positive ones (Fig. 5E). Similar results can be seen with other HaloTag-ligand combinations (data not shown).

We next reanalyzed the data for TMR-only, Oregon Green-only, and TMR and Oregon Green double-positive aggregates. In the presence of dox, re-analysis had little impact, given that no substantial levels of mutant protein were being newly created (Fig. S3A). In contrast, under conditions of constitutive expression, segregating the TMR and Oregon Green double-positive aggregates revealed that TMR-only aggregates were eliminated within 72 h (Fig. 5F), which is similar to the rate observed in the presence of dox (Fig. 3D). Unlike dox-treatment, however, many of the TMR-only structures evolved into TMR and Oregon Green double-positive aggregates, indicating that addition of newly formed Oregon-Green-positive protein onto pre-existing TMR-positive aggregates accounts for the diminished clearance observed in Fig. 5D. The sum of TMR-only, TMR and Oregon Green double-positive, and Oregon Green-only aggregates were the same across all time points, confirming that the system had reached steady state (Fig. S3B).

These data signify that in order to be degraded, aggregates must reach a state at which they no longer can incorporate newly synthesized protein. Analysis of the Oregon-Green-only structures revealed that aggregates can form de novo in the background of aggregate clearance and aggregate growth; however, during the time at which preformed inclusions are present, consolidation of newly formed protein into pre-existing aggregates is dominant to the formation of new ones. In summary, our analyses reveal that by using HaloTag to temporally label the aggregation-prone proteins, we can distinguish how aggregation evolves in the cell, and at what stage these structures can finally be eliminated.

**HspB7 affects aggregate formation and AlfyC affects aggregate clearance**

Having established our exon1Htt103Q–HaloTag cell line, we returned to HspB7 and AlfyC to test the hypothesis that HspB7 interferes with aggregate formation whereas AlfyC affects aggregate clearance (Fig. 6). We first examined the overexpression of HspB7 (Fig. 6A–C). HspB7 was transfected into exon1Htt103Q–HaloTag cells that were labeled with TMR to label the existing protein and aggregates. At 72 h post-transfection, cells were labeled with Oregon Green, then fixed and analyzed. Confirming our findings in 17aaHttpolyQ–mCFP cells (Fig. 2), HspB7 overexpression had no effect on the total number of aggregates (Fig. 6B). When broken down by ligand, HspB7 had no effect on TMR-only structures, no effect on TMR and Oregon Green double-positive structures but a significant effect on Oregon-Green-only structures. These data indicate that once an aggregate forms, HspB7 has little impact on its turnover (TMR-only), and cannot disrupt the further oligomerization of aggregates (both TMR and Oregon Green). By contrast, HspB7 reduced de novo formation of aggregates as revealed by the reduction of Oregon-Green-only structures. Nonetheless, they are but a small percentage of the total aggregates present (Fig. 6C), and thus there was little impact on the total aggregate population. This is consistent with what has been reported previously (Vos et al., 2010) and what we find here, that is, co-transfection of HspB7 with the aggregation-prone protein leads to a dramatic impact on aggregation by affecting the formation of SDS-insoluble inclusions. Although HspB7 continues to exert its function in Fig. 2, its effect is masked by the fact that very few aggregates are formed de novo in the presence of preformed inclusions. By using the HaloTag, this distinction could be observed.

We next examined the effect of AlfyC using the same protocol outlined above (Fig. 6D–F). Overexpression of AlfyC significantly decreased the total number of aggregates, and does so by decreasing TMR-only preformed inclusions and modestly reducing Oregon-Green-only inclusions. Interestingly, the overexpression of Alfy had no effect on the total number of TMR and Oregon Green double-positive structures. Taken together with Fig. 5, these data suggest that AlfyC can recognize protein aggregates that are preformed or newly formed and target them for degradation; however, aggregates that also contain newly formed proteins are somehow not available for Alfy-mediated targeting, thus limiting the efficacy of Alfy. Although it is possible that smaller, discrete TMR-only or Oregon-Green-only structures within the TMR and Oregon Green double-positive aggregates are being targeted for degradation, the efficiency is not such that the total number of TMR Oregon Green double-positive structures is diminished. Given that this latter pool of double-positive structures represent the clear majority of aggregates, identifying modifiers that affect this pool might have the greatest impact on aggregate burden.
Fig. 5. Exon1Htt103Q–HaloTag cell lines can be used to monitor aggregate formation, growth and clearance under the continuous presence of polyQ protein. (A) Schematic of the experiment design. Cells were exposed to 0.5 μM TMR (red) for 30 min. Prior to collection at the times indicated, cells were also exposed to Oregon Green (OG, green) for 30 min. (B–D) Representative images [at 0 h (B), 24, 48, 72 and 96 h (C)] and quantification (D) of TMR- or Oregon Green-positive aggregates. Areas highlighted in the white box are shown at higher magnification below the respective image. Cells reveal that aggregate clearance can occur during continuous expression of exon1Htt103Q–HaloTag. At 0 h all aggregates are TMR-positive with little to no detectable Oregon-Green-positive structures. As time progresses, there is a gradual shift such that after 96 h most of the TMR-positive aggregates are cleared and are positive for Oregon Green. (E,F) Under conditions of continuous expression, aggregates can be positive for two different HaloTag ligands. (E) Representative image of a coumarin-positive aggregate, which continued to grow to incorporate new TMR-positive exon1Htt103Q–HaloTag protein. 24 h after coumarin, TMR was administered to label this newly expressed protein. (F) Re-analysis of the data represented in D to include TMR-only, TMR and Oregon Green double-positive and Oregon-Green-only aggregates reveals that TMR-only aggregates are short lived and are either cleared or continue to further incorporate protein. By 96 h, most of the TMR-containing aggregates are eliminated and become mostly only positive for Oregon Green. Nuclei are stained with Hoechst 33342 (blue). Data represented as mean±s.d. from n=4 independent experiments. An average of 1000 cells per time point was counted. Scale bars: 10 μm.
**DISCUSSION**

The aberrant accumulation of aggregated proteins and their potential link to toxicity makes identifying modifiers of protein accumulation an attractive therapeutic target. Furthermore, understanding how these modifiers exert their mechanism of action is likely to be more beneficial than simply measuring aggregate load as a final outcome. By using irreversible labeling with a variety of fluorophore-based HaloTag ligands, we have been able to gain a greater understanding of the accumulation of a class of aggregation-prone proteins. We have found that preformed inclusions are degraded both in the...
presence and absence of newly synthesized protein, and that aggregates must reach a degradation-competent state to be targeted for elimination. Moreover, by examining the influence of two proteins previously described to inhibit protein accumulation similarly, we have been able to demonstrate that comparable outcomes can be reached by affecting discrete stages of protein accumulation and clearance.

This study highlights several points. First, we introduce a novel method by which we can distinguish how a given pathway or modifier affects protein accumulation. Different degradation pathways have been implicated in affecting the accumulation of aggregation-prone proteins, from proteasome-mediated degradation (Mishra et al., 2008; Iwata et al., 2009; Zhang et al., 2010; Urushitani et al., 2010; Ortega and Lucas, 2014; Schipper-Krom et al., 2014) to the lysosome-mediated pathway or macroautophagy as being the predominant pathway for aggregate clearance (Ravikumar et al., 2002; Iwata et al., 2005b; Yamamoto et al., 2006; Pankiv et al., 2007; Lamark et al., 2009; Fan et al., 2010; Lamark and Johansen, 2012; Odagiri et al., 2012; Castillo et al., 2014; Bae et al., 2014). Our ability to interrogate how each pathway might contribute to aggregate turnover has been limited by our inability to temporally characterize aggregate formation and clearance in cells. For example, although several studies indicate that macroautophagy eliminates aggregated proteins, the underlying molecular mechanism remains unclear. Currently, several molecular scaffolding proteins have been implicated in the process (Mijaljica et al., 2012; Lamark and Johansen, 2012; Rogov et al., 2014). We find that the molecular scaffold Alfy, which bridges the ubiquitylated protein with the core machinery involved in autophagosome formation (Filimonenko et al., 2010), targets aggregated structures for degradation rather than the detergent-soluble form. Moreover, the aggregates that can be targeted must be static and inert to newly synthesized aggregating proteins. Using a similar approach, the impact of the other implicated scaffolds, such as p62 (also known as SQSTM1) (Pankiv et al., 2007), NBR1 (Kirk et al., 2009) and others (Korac et al., 2013; Rogov et al., 2014), can be examined with our newly created assay, to establish temporally when these scaffolds influence clearance. Further study might also determine how an aggregate transitions from a degradation-competent, TMR-only state to a TMR and Oregon Green double-positive state. One weakness of our approach, however, is that it is currently difficult to achieve sub-saturation levels of fluorescent intensity of a given dye, thus the actual amounts of protein rather than number of aggregated structures is difficult to interpret. The development of a dark HaloTag dye would help to dilute the amount of fluorescent dye used without affecting our ability to fully occupy the binding sites in the HaloTag. Nonetheless, our findings strongly suggest that even simply examining the number of structures transitioning between the two aggregated states might lead to strategies that will hasten the clearance of these otherwise persistent structures.

Next, our data revealed that even the most robust modifiers of aggregate formation can have a minimal effect on preformed inclusions. Of all the small heat-shock proteins examined, HspB7 was the most potent inhibitor of aggregation (Vos et al., 2010). Despite this, we found that in the presence of preformed inclusions, the ability of HspB7 to reduce aggregate load is minimal. Our findings suggest that HspB7 prevents the de novo formation of aggregates, but once preformed inclusions are present, newly formed aggregates make a relatively small contribution to total aggregate load, and thus the impact of HspB7 is lost. Although HspB7 affected a pre-aggregated structure, surprisingly, the chaperone did not prevent aggregate growth. This implies that HspB7 either affects newly formed aggregates by preventing the seeding event, or cannot sufficiently inhibit aggregate growth because the rate of oligomer incorporation is too great.

In summary, the final outcome of aggregate load is the sum of a complex series of discrete cellular events that can be differentially affected by modifiers. Although the ultimate goal of therapeutic approaches to treat neurodegeneration may be to diminish the abnormal accumulation of ubiquitylated proteins, simply focusing on this final outcome might mask the mechanism by which aggregate load is affected, which in turn might lead to disappointing outcomes when tested under physiological conditions. To overcome these limitations, we created an inducible stable cell line that temporally labels the aggregating protein to expose how a modifier influences aggregate load, and revealed that the mechanism of action, and hence therapeutic potential, of two apparently similarly acting proteins were quite distinct. Moreover, this assay revealed that the growing aggregate pool represents the majority of aggregates under conditions where aggregates are already present, thus leading to the prediction that identification of modifiers that prevent aggregates from incorporated newly formed proteins will have the greatest impact on aggregate burden and thus disease progression.

**MATERIALS AND METHODS**

**Antibodies**

The following antibodies were used for immunoblotting and/or FTA: rabbit anti-FLAG ([polyclonal, 1:400 (2.5 μg/ml); Sigma]; mouse anti-GFP ([polyclonal, 1:1000; Roche]); chicken anti-GFP ([1:1000; Abcam]); rabbit anti-HaloTag ([1:500; Promega]; mouse anti-HspB7 ([1:500; Abnova]); rabbit anti-LC3B ([ab48394, 1:1000; Abcam]); and rabbit anti-vinculin ([1:5000; Life Technologies]). Mouse anti-EM48 ([1:100; EMD Millipore, Billerica, MA) was used for immunofluorescence.

**Plasmids**

HspB7 and Alfyc constructs were created as previously described (Filimonenko et al., 2010; Vos et al., 2010). The Exon1 htt103Q construct with alternating CAGCAA repeats was received from Alexei Kazantsev (MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, USA) (Kazantsev et al., 1999). Exon1 htt103Q–HaloTag construct was created by subcloning Exon1 htt103Q into pHT2 (Promega) using the restriction enzymes Nhel and BamHI. This was subsequently subcloned into the Nhel/Nael sites in the pB4 TetO inducible vector (Baron et al., 1995).

**Cell**

HeLa cell cultures were maintained in high-glucose Dulbecco’s modified eagle medium (DMEM; Life Technologies) supplemented with 10% fetal bovine serum (FBS; Life Technologies) at 37°C and in a 5% CO2-containing atmosphere. 17aaHtt-polyQ–mCFP cell lines were maintained using 100 μg/ml of hygromycin (Life Technologies) and 50 μg/ml of G418 (Life Technologies) as described previously (Yamamoto et al., 2006). Lysosome inhibition was achieved using chloroquine (Chlor) (10 μM, Sigma). All cell lines were confirmed by PCR to be negative for mycoplasma, and are grown in the absence of penicillin and streptomycin.

**Transfection**

Cells were plated in a 6- or 24-wells plate and transfected 24 h later with Alfyc or HspB7 plasmid DNA alone using Lipofectamine (Life Technologies) or co-transfected with 17aaHtt65Q–mCFP or 17aaHtt103Q–mCFP using Lipofectamine 2000 (Life Technologies) according to the manufacturer’s protocol. Single plasmid transfections were conducted with 1.0 μg of plasmid DNA in six-wells plates and 0.3 μg of plasmid DNA in 24-wells plates. Co-transfections were performed using 0.5 μg of 17aaHtt103Q–mCFP and 1.0 μg HspB7 or Alfyc plasmid DNA. Cells were incubated with transfection medium for 5 h then changed into DMEM with 10% FBS
overnight. Cells were collected and analyzed as described in the respective figure legends. Briefly, for image-based analyses, cells were plated onto coverslips, treated as described, then mounted with ProLong Antifade Gold with DAPI (Molecular Probes).

**Primary neurons**

The use of GFP–LC3-expressing mice (Mizushima et al., 2004) complied with the Guide for Care and Use of Laboratory Animals and were approved by the IACUC committee at Columbia University. Mice were maintained in a 12-h-light–12-h-dark cycle in a temperature and humidity controlled environment, with *ad libitum* access to food and water. GFP–LC3-expressing mice (C57BL/6) were maintained as homozygous and genotyped as described previously (Kuma and Mizushima, 2008). Primary dissociated cortical cultures were prepared from postnatal day 0 (P0) pups. The cortical lobes were dissected in ice cold DMEM/F12 (Life Technologies) containing 10% heat-inactivated FBS and trypsinized for 30 min at 37°C, then triturated in fresh 10% FBS DMEM/F12 through a fire-polished glass pipette and filtered through a 40-μm nylon cell strainer. For transient transfection, cells were plated at a density of 1.0×10⁶ cells/well onto coverslips coated with 20 μg/ml poly-D-lysine (Sigma) and 5 μg/ml mouse laminin (Life Technologies). The medium was changed 2 h after plating to Neurobasal medium (Life Technologies) containing 0.5 mM L-glutamine, 1× B27 supplement (Life Technologies), 2% heat-inactivated FBS and 1× antibiotic (Life Technologies). 1.5 μM coumarin HaloTag ligand (Promega) was added to the medium 24 h post-transfection for 1 h, followed by a complete change in medium. After 24 h 500 nM TMR HaloTag ligand (Promega) was added for 30 min and cells were fixed in 4% paraformaldehyde in PBS and mounted under coverslips with Prolong Antifade Gold (Life Technologies). The exon1Htt103Q–HaloTag inducible cell line was created from the polyQ–HaloTag cell line using methods previously described (Cremona et al., 2011; Yamamoto et al., 2006). Briefly, pBi4-exon1Htt103Q-HT was co-transfected at a 1:10 ratio with Ptk-hygro into tTA-positive HeLa cells (Clontech). Selection of clones was achieved by using 800 μg ml⁻¹ of G418. 500 nM TMR HaloTag ligand (Promega) was added for 30 min and cells were fixed in 4% paraformaldehyde in PBS and mounted under coverslips with Prolong Antifade Gold (Life Technologies).

**Western blotting and FTA**

Sample preparation

Cells were washed with PBS, trypsinized and pelleted. Cells were lysed in 1% PBS with Triton X-100 containing 8 M Urea, 5 mM EDTA, 100 mM NaCl and 50 mM Tris-HCl, and incubated on ice for 20 min. 1× protease/phosphatase inhibitor cocktail (Thermo Fisher Scientific) was freshly added each time to the lysis buffer. Transiently transfected polyQ samples were centrifuged at 20,817 g and washed three times with PBS containing 1% Tween-20 and 3% BSA at room temperature, and probed overnight with primary antibodies at 4°C. Next day, membranes were washed three times with PBS containing 1% Tween-20 and incubated for 1 h with horseradish peroxidase (HRP)-conjugated secondary antibodies (Thermo Fisher Scientific) at a dilution of 1:5000 to 1:10,000. Signal was detected with SuperSignal WestDura Substrates (Thermo Fisher Scientific). Blots were developed using the VersaDoc Imaging system (Bio-Rad). The intensities of the different bands were measured using the software provided by the VersaDoc Imaging system.

**Filter trap assay**

Either three- or five-fold dilutions of protein was prepared and slotted onto a pre-washed (PBS 0.1% SDS) 0.2 μm cellulose acetate membrane (0.2 μm pore size, GE Healthcare Life Sciences, Marlborough, MA) using a Bio-Dot 29 microfiltration apparatus (Bio-Rad). Gentle suction was applied to trap the detergent and urea-insoluble protein. Membranes were then removed and washed three times with PBS containing 0.1% SDS, and blocked in PBS containing 1% Tween-20 with 3% BSA at for at least 2 h room temperature or overnight at 4°C, then processed in the same manner as for immunoblotting described above.

**Aggregate counting**

Cells readied for image-based analysis were plated on glass coverslips then processed as described in the figure legends. After the allotted time, coverslips were washed with PBS containing 100 μM CaCl₂ and 1 mM MgCl₂ then fixed with 4% paraformaldehyde in PBS. Nuclei were stained using 1 μg/ml Hoechst 33342 (Life Technologies) for 10 min. After three washing steps with PBS, the coverslips were mounted using ProLong Antifade Gold (Life Technologies). The images were acquired using a Leica SP5 confocal microscope (fields were acquired randomly, and adequate cell numbers were confirmed by imaging for Hoechst 33342) and counting of the aggregates was performed using ImageJ (NIH). For the quantification of these experiments, a minimum of 100 cells per condition per experiment were counted.

**Statistical analyses, figure creation and software used**

One or two-way two-tailed analyses of variance (ANOVA) were performed unless otherwise noted. All statistical analyses were performed using Statview 5.0 (SAS Institute, Cary, NC). The respective *p*-values were ascertained using power analyses. Adobe Creative Suite 5 (Photoshop and Illustrator) were used to create all figures, whereas quantification was performed using ImageJ (NIH).

**Acknowledgements**

We would like to thank the Kampinga and Yamamoto laboratories for their helpful input and critical reading of this manuscript.

**Competing interests**

The authors declare no competing or financial interests.

**Author contributions**

J.M.D. and E.E. conducted experiments; J.M.D., E.E., H.H.K. and A.Y. designed experiments and methodologies; E.E. and A.Y. analyzed data; E.E. and A.Y. wrote the manuscript.

**Funding**

This work was supported by the National Institutes of Health [grant numbers RO1 NS063973 to A.Y., RO1NS077111 to A.Y.]; Parkinson’s Disease Foundation (to A.Y.); Princes Beatix Foundation (to E.E.); and the Marco Polo Fund, University of Groningen (to E.E. and H.H.K.). Deposited in PMC for release after 12 months.

**Supplementary information**

Supplementary information available online at http://jcs.biologists.org/lookup/suppl/doi:10.1242/jcs.179978/-/DC1

**References**


